Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-10-28

Clinical Trial Update: Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2a trial of a Plasmodium falciparum GAP p52/p36 sporozoite malaria vaccine was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pf GAP p52-/p36- Sporozoite Malaria Vaccine

Snippet

Sponsor: Seattle Children's Hospital | Conditions: Malaria | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-10-28